Famatiga E - Search Results

1

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R, et al. Morton DL, et al. Among authors: famatiga e. Ann Surg. 1992 Oct;216(4):463-82. doi: 10.1097/00000658-199210000-00010. Ann Surg. 1992. PMID: 1417196 Free PMC article. Clinical Trial.

2

Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.

Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL. Hsueh EC, et al. Among authors: famatiga e. Ann Surg Oncol. 2004 Oct;11(10):892-9. doi: 10.1245/ASO.2004.02.018. Epub 2004 Sep 20. Ann Surg Oncol. 2004. PMID: 15383418

3

Active specific immunotherapy in malignant melanoma.

Morton DL, Foshag LJ, Nizze JA, Gupta RK, Famatiga E, Hoon DS, Irie RF. Morton DL, et al. Among authors: famatiga e. Semin Surg Oncol. 1989;5(6):420-5. doi: 10.1002/ssu.2980050608. Semin Surg Oncol. 1989. PMID: 2531908 Review.

4

Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.

Barth A, Hoon DS, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL. Barth A, et al. Among authors: famatiga e. Cancer Res. 1994 Jul 1;54(13):3342-5. Cancer Res. 1994. PMID: 8012946

5

Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma.

Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R. Morton DL, et al. Among authors: famatiga e. Ann N Y Acad Sci. 1993 Aug 12;690:120-34. doi: 10.1111/j.1749-6632.1993.tb44002.x. Ann N Y Acad Sci. 1993. PMID: 8368731 Clinical Trial. No abstract available.

6

Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival.

Hsueh EC, Famatiga E, Gupta RK, Qi K, Morton DL. Hsueh EC, et al. Among authors: famatiga e. Ann Surg Oncol. 1998 Oct-Nov;5(7):595-602. doi: 10.1007/BF02303828. Ann Surg Oncol. 1998. PMID: 9831107

7

Immunological aspects of retinoids in humans. III. Effects of retinoic acid on the natural killing of tumor cells.

Sidell N, Famatiga E, Shau H, Golub SH. Sidell N, et al. Among authors: famatiga e. J Biol Response Mod. 1985 Jun;4(3):240-50. J Biol Response Mod. 1985. PMID: 3160830

8

Immunological aspects of retinoids in humans. II. Retinoic acid enhances induction of hemolytic plaque-forming cells.

Sidell N, Famatiga E, Golub SH. Sidell N, et al. Among authors: famatiga e. Cell Immunol. 1984 Oct 15;88(2):374-81. doi: 10.1016/0008-8749(84)90170-9. Cell Immunol. 1984. PMID: 6386185

9

Augmentation of human thymocyte proliferative responses by retinoic acid.

Sidell N, Famatiga E, Golub SH. Sidell N, et al. Among authors: famatiga e. Exp Cell Biol. 1981;49(5):239-45. doi: 10.1159/000163828. Exp Cell Biol. 1981. PMID: 6974663

10

Leptospirosis in animals and man in the Philppines. VIII. Serological incidence in native dogs.

Topacio TM, Gavino LG, Famatiga E, Suva M. Topacio TM, et al. Among authors: famatiga e. Int J Zoonoses. 1974 Jun;1(1):32-42. Int J Zoonoses. 1974. PMID: 4468962 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters